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Pref-1 is an EGF repeat-containing transmembrane
protein that produces a biologically active soluble
form by TACE-mediated cleavage. Although Pref-1
inhibition of adipogenesis has been well established,
the specific target(s) of Pref-1 or the Pref-1 function in
mesenchymal cell commitment/differentiation are
not known. Here, we show that Sox9 downregulation
is required for adipocyte differentiation and that
Pref-1 inhibits adipocytedifferentiation throughupre-
gulating Sox9 expression. Sox9 directly binds to the
promoter regionsofC/EBPbandC/EBPd to suppress
their promoter activity, preventing adipocyte differ-
entiation. Furthermore, we also show that, by
inducingSox9, Pref-1 promotes chondrogenic induc-
tion of mesenchymal cells but prevents chondrocyte
maturation as well as osteoblast differentiation, with
supporting in vivo evidence in Pref-1 null and Pref-1
transgenic mice. Thus, Sox9 is a Pref-1 target, and
Pref-1 directs multipotent mesenchymal cells to the
chondrogenic lineage but inhibits differentiation into
adipocytes as well as osteoblasts and chondrocytes.
INTRODUCTION
Preadipocyte factor 1 (Pref-1)wasoriginally clonedbyusasapre-
adipocyte transmembrane protein that inhibits adipogenesis
(Smas and Sul, 1993). The full-length form of Pref-1 (Pref-1A) is
a protein of 385 amino acids. Pref-1 contains an extracellular
domain with six EGF-like repeats, a juxtamembrane region,
a single transmembrane domain, and a short cytoplasmic tail
(Smas et al., 1994). The extracellular domain of Pref-1 is cleaved
from Pref-1 by a disintegrin and metalloproteinase 17 (ADAM17,
also named TNF-a converting enzyme [TACE]) to generate the
biologically active soluble Pref-1 (Mei et al., 2002; Smas et al.,
1997; Wang and Sul, 2006). Pref-1 mRNA and protein levels are
high in 3T3-L1 preadipocytes, but Pref-1 expression decreases
during adipocyte differentiation and is absent in mature adipo-
cytes.Dexamethasone (DEX), a component of adipogenic agents
routinely used for adipocyte differentiation, suppresses Pref-1
expression. Thus, Pref-1 is commonly used as a unique preadi-
pocyte marker. Constitutive expression of Pref-1 inhibits adipo-
cyte differentiation, and absence of Pref-1 accelerates/increases
the degree of adipocyte differentiation in cultured cells (Smas
et al., 1999; Smas and Sul, 1993). Although the direct target ofCPref-1 is not known, Pref-1 activates ERK/MAPK to inhibit adipo-
cyte differentiation (Kim et al., 2007). The function of Pref-1 in adi-
pogenesis in vivo has been firmly established. Pref-1 null mice
display enhanced adipose tissue formation with higher expres-
sion of adipocyte markers, showing increased circulating lipid
levels, a characteristic usually associated with obesity (Moon
et al., 2002). Conversely, overexpression of Pref-1 in adipose
tissue decreases adipose tissue mass and impairs adipocyte
differentiation (Lee et al., 2003). In adults, Pref-1 expression is
restricted mainly to preadipocytes of adipose tissue, although
Pref-1 is detected in some neuroendocrine cell types and was
identified as a gene (dlk1) expressed in neuroblastoma cells
(Laborda et al., 1993). During embryonic development, however,
Pref-1 is widely expressed in multiple embryonic tissues,
including liver, lung, and developing vertebra. Thus, the soluble
form of Pref-1 has been purified from fetal circulation and named
as fetal antigen 1 (FA1) (Bachmann et al., 1996). Pref-1 is coded
by a paternally expressed imprinted gene, and a majority of im-
printed genes code for proteins that regulate fetal growth and
organogenesis (da Rocha and Ferguson-Smith, 2004). Although
Pref-1 function in embryonic development has not been studied,
we observed defects in bone development in both Pref-1 null and
Pref-1 transgenic mice (Lee et al., 2003; Moon et al., 2002).
Multipotent mesenchymal cells can commit and differentiate
into various cell types, including adipocytes, chondrocytes, and
osteoblasts (Gesta et al., 2007). Adipogenesis occurs late in
embryonic development and in postnatal periods. C/EBPa and
PPARg play critical roles in adipogenesis and induction of adipo-
cyte markers, including adipocyte fatty acid-binding protein
(aP2/FABP4) (Farmer, 2006; Gregoire et al., 1998; Rosen and
MacDougald, 2006). Chondrogenesis and osteogenesis during
skeletal development, however, occur in early embryonic stages.
Chondrogenesis occurs frommesenchymal condensations, and
osteogenesis of some bones occurs directly from mesenchymal
condensations by intramembranous ossification. Most bones,
however, are formed by endochondral ossification. Mesen-
chymal condensations first become immature chondrocytes
that undergo maturation to become hypertrophic, when some
of the surrounding mesenchymal cells invade the zone of hyper-
trophic chondrocytes to become osteoblasts. Sox9 is required
for mesenchymal condensation and for initiation of early chon-
drogenesis to generate immature chondrocytes that express
cartilaginous matrix proteins, such as type II and IX collagens
(Col) and aggrecan (Akiyama et al., 2004; Bi et al., 2001). Thus,
Sox9 is expressed in all chondro-osteoprogenitor cells and in
mesenchymal condensations and promotes chondrogenic
commitment. During chondrocyte hypertrophy and early osteo-
genesis, Runx2 is upregulated, and Col X and osteocalcin areell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc. 287
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a prerequisite for chondrocyte maturation and osteogenesis.
Sox9, therefore, plays a critical role in skeletogenesis. Since
Sox9 is found in chondro-osteoprogenitor cells and regulates
skeletogenesis, it is possible that Sox9may also affect differenti-
ation of adipocytes that are derived from the common mesen-
chymal cells, but this possibility has not been examined before.
The present study was to elucidate the molecular target and
effect on mesenchymal cell commitment/differentiation by
Pref-1. Here, we show that Sox9 directly binds to C/EBPb and
C/EBPd promoters to suppress their promoter activity, prevent-
ing adipocyte differentiation. Thus, constitutive Sox9 expression
inhibits and Sox9 knockdown enhances adipocyte differentia-
tion. More importantly, Pref-1 inhibition of adipose conversion
is by preventing Sox9 downregulation. Furthermore, by inducing
Sox9, Pref-1 promotes chondrogenic induction of mesenchymal
cells to generate immature chondrocytes, but Pref-1 inhibits
chondrocyte maturation as well as osteoblast differentiation.
Overall, by inducing Sox9, Pref-1 promotes the chondrogenic
commitment of mesenchymal cells but inhibits adipocyte,
chondrocyte, and osteoblast differentiation.
RESULTS
Sox9 Downregulation Is Required for Adipocyte
Differentiation, and Pref-1 Inhibition Is through Sox9
Regulation
During the search for Pref-1 targets by microarray analysis and
other candidate approaches, we detected regulation of Sox9
expression by Pref-1. We found that treatment of Pref-1 null
MEFs with Pref-1-hFc increased Sox9 expression rapidly by
4-fold within 1 hr, and this high level of expression was main-
tained for up to 4 hr (Figure 1A). A similar increase in Sox9 at
the protein level is also detected. Pref-1 treatment increased
Sox9 expression in multipotent mesenchymal C3H10T1/2 cells
as well as in 3T3-L1 preadipocytes (data not shown). Expression
of other factors with documented effects on embryonic develop-
ment, such as Smad1 and Smad6 for TGFb/BMP family, re-
mained the same upon Pref-1 treatment. TNFa, a cytokine that
can inhibit adipocyte differentiation, also was ineffective in upre-
gulating Sox9, suggesting that upregulation of Sox9 is Pref-1
specific. We previously have shown that Pref-1 inhibition of
adipocyte differentiation is through Pref-1-mediated ERK1/2
activation. Therefore, we examined whether ERK1/2 phosphory-
lation is required for Pref-1 induction of Sox9 (Figure 1B). As
previously shown, Pref-1 treatment transiently increased
ERK1/2 phosphorylation at 30 min of Pref-1 treatment in Pref-1
null MEFs but decreased to basal levels after 4 hr. In these cells,Figure 1. Pref-1 Regulates Sox9 Expression
(A) Regulation of Sox9 expression by Pref-1. Coomassie staining of purified Pref-1
treated with 50 nM Pref-1-hFc or 50 ng/ml TNFa. Results are mean ± SEM. **p <
(B) Western blotting of cells with Pref-1-hFc treatment (a), ERK1/2 inhibitor (b), a
(C) RT-PCR for adipose tissue (Ad tissue), stromal vascular fraction (SVF), and ad
(D) Pref-1 regulates Sox9 expression during adipocyte differentiation.
(E) Comparison of adipocyte differentiation of MEFs from Pref-1 null, wild-type, a
Western blot analysis (middle panels) in MEFs at confluence. The value for wild-
to wild-type MEFs. Microscopic morphology, oil red O staining (right upper panels
markers by RT-PCR 8 days after induction of adipocyte differentiation (right lowe
Cwe detected an increase in Sox9 protein level 30 min after Pref-1
treatment, and the Sox9 level was further increased at 4 hr. Thus,
ERK phosphorylation/activation by Pref-1 appears to precede
Sox9 induction. When we treated these cells with MEK inhibitors
PD98059 or U0126, we did not observe any increase in Sox9
levels upon Pref-1 treatment. Similarly, siRNA-mediated knock-
down of ERK1/2 prevented the increase in Sox9 level by Pref-1
treatment. Overall, these results demonstrate that, by activating
ERK1/2, Pref-1 induces Sox9 expression.
Expression of Sox9 was easily detected in adipose tissue
(Figure 1C). However, unlike adipocyte markers such as adipo-
nectin and leptin, Sox9 mRNA was not detected in adipocyte
fraction but was found in stromal vascular fraction that contains
preadipocytes as well as other cell types such as macrophages/
endothelial cells. Interestingly, Sox9 mRNA levels were lower in
adipose tissue from high-fat diet-induced as well as genetically
obese ob/ob mice (Figure S2 available online). In this regard,
mRNA levels of preadipocyte marker, Pref-1, were lower in
adipose tissue from these obese mouse models, whereas
mRNA levels of various adipocyte markers such as C/EBPa,
PPARg, and leptin were higher. We next examined Sox9 expres-
sion during MEF differentiation into adipocytes (Figure 1D). As
expected, upon treatment with adipogenic agents DEX/MIX,
there was a time-dependent increase in expression levels of adi-
pogenic transcription factors, C/EBPa and PPARg, as well as
other adipocyte markers, including FAS, adiponectin, and leptin,
as MEFs underwent adipocyte differentiation. As we have re-
ported previously, unlike the decrease observed during 3T3-L1
adipocyte differentiation, during MEF differentiation, Pref-1
expression displayed a transient increase at day 1 but rapidly
decreased and was not detectable at day 5 after conversion
into adipocytes. Interestingly, we found that the Sox9 expression
also was transiently increased and then decreased during MEF
differentiation, closely following the Pref-1 expression. Protein
levels of Sox9 and Pref-1 showed a similar pattern, although
the decrease was slower than that observed for mRNA levels
(Figure 1D, right panels). The difference in the time course of
Pref-1 downregulation during adipocyte differentiation between
MEFs and 3T3-L1 cells has been noticed previously (Kim et al.,
2007; Smas et al., 1999). In this regard, unlike 3T3-L1 cells that
are committed to adipocyte lineage, MEFs are multipotent
mesenchymal cells, and Pref-1 levels may increase during
commitment to adipocyte lineage when these cells are treated
with adipogenic agents. Likewise, Sox9 expression may be tran-
siently induced in this culture condition. Regardless, the parallel
patterns of Pref-1 and Sox9 expression support a notion that
Pref-1 regulates Sox9 expression, thereby inhibiting adipocyte
differentiation.-hFc (a). RT-PCR (b), RT-qPCR (c), and western blotting (d) in Pref-1 null MEFs
0.01 compared to that before treatment.
nd ERK1/2 siRNA transfection (c).
ipocyte fraction (Ad F).
nd aP2-Pref-1 transgenic embryos. Northern blot (left panel), RT-qPCR, and
type MEFs was defined as 1. Results are mean ± SEM. **p < 0.01 compared
), and adipogenic transcription factors by northern blotting and late adipocyte
r panels).
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null, wild-type, and aP2-Pref-1 transgenic mice (Figure 1E).
Correlating with Pref-1 expression, Sox9 mRNA and protein
levels were 50% lower in Pref-1 null MEFs than in wild-type
MEFs, whereas those in Pref-1 transgenic MEFs were 2-fold
higher than in wild-type MEFs. After treatment with adipogenic
agents, 80% of Pref-1 null MEFs differentiated into adipocytes,
whereas 50% of wild-type MEFs and 20% of Pref-1 transgenic
MEFs differentiated as judged by the rounded adipocyte
morphology. Oil red O staining for lipid accumulation displayed
corresponding differences in the degree of adipocyte differenti-
ation. Likewise, following differentiation, mRNA levels of C/EBPa
and PPARg in Pref-1 null MEFs were 2-fold higher than those in
wild-type MEFs, and levels in Pref-1 transgenic MEFs were
65%–70% lower than in wild-type MEFs, reflecting the differ-
ences in adipocyte differentiation. As expected, Pref-1 expres-
sion was not detected in Pref-1 null MEFs and was completely
suppressed in wild-type MEFs during adipocyte differentiation.
On the other hand, Pref-1 transgenic MEFs showed a high level
of Pref-1 expression due to inhibition of differentiation in addition
to expression from the transgene. Overall, these results show
that Pref-1 and Sox9 expression changes in a parallel fashion
during differentiation and is inversely correlated with the degree
of differentiation of MEFs into adipocytes.
We next employed soluble Pref-1-hFc in Pref-1 null MEFs to
test whether inhibition of adipocyte differentiation by Pref-1
accompanies changes in Sox9 expression (Figure 2A). Pref-1-
hFc caused a marked decrease in adipocyte differentiation as
judged by Oil red O staining and expression of adipocyte
markers, including adiponectin and leptin. In control hFc-treated
cells, C/EBPa and PPARg levels increased by 10- and 5-fold,
respectively, whereas, in Pref-1-hFc treated cells, C/EBPa levels
increased by only 1.8-fold, and PPARg expression did not
change. We found that Sox9 expression was drastically
decreased by 90% during adipocyte differentiation in control
hFc-treated cells, whereas, in Pref-1-hFc treated cells, Sox9
expression did not change and remained at levels seen prior to
treatment with adipogenic agents. We also examined Pref-1
and Sox9 expression during differentiation of wild-type MEFs
into adipocytes (Figure S3). Pref-1 and Sox9 mRNA levels
increased 3-fold at day 1 (after DEX/MIX treatment) and then
decreased precipitously to very low levels upon differentiation.
In cells treated with Pref-1-hFc, the expression levels also
decreased but did so slowly and not below those in preadipo-
cytes. Overall, these results show that, during Pref-1 inhibition
of adipocyte differentiation of MEFs, Pref-1 prevents the
decrease inSox9expression that normally occursduring adipose
conversion.
Next, we tested the role of Sox9 in adipocyte differentiation of
Pref-1 null MEFs by infecting Sox9 lentivirus. The high levels
of Sox9 in nucleus after lentivirus infection were first verified
(Figure 2B), and Sox9 expression driven by the CMV promoter
would remain the same during differentiation. Upon treatment
of Pref-1 null MEFs with adipogenic agents, more than 80% of
cells infected with control empty lentivirus differentiated into
adipocytes, whereas only 40% of cells infected with Sox9 lenti-
virus differentiated, as judged by morphology and expression of
the adipocyte markers FAS, adiponectin, and leptin and adipo-
genic transcription factors. Thus, Sox9 lentivirus-infected cells290 Cell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc.had 70% lower C/EBPa and PPARg levels compared to empty
lentivirus-infected cells after adipose conversion (Figure 2C).
We conclude that constitutive overexpression of Sox9 inhibits
adipocyte differentiation. Furthermore, Sox9 lentivirus-infected
cells treated with Pref-1-hFc showed a similar degree of adipo-
cyte differentiation to that observed in cells infected with Sox9
lentivirus alone. This observation indicates that Pref-1 and
Sox9 did not have additive effects on adipocyte differentiation,
suggesting a common underlying mechanism for inhibition of
adipocyte differentiation.
We next employed 3T3-L1 cells to test the role of Pref-1 and
Sox9 in adipocyte differentiation. As expected, during 3T3-L1
differentiation, various adipocyte markers such as FAS, adipo-
nectin, and leptin increased late during differentiation, whereas
the increase in C/EBPa and PPARg expression was detected
somewhat earlier and continued to increase up to day 5 (Fig-
ure 3Aa). Expression of C/EBPb and C/EBPd increased even
earlier, by 16- and 10-fold, respectively, 24 hr after the addition
of adipogenic agents (Figure 3Ab). On the other hand, both
Pref-1 and Sox9 expression decreased in parallel by 50% 12 hr
after the addition of adipogenic agents and further decreased by
80%–90% by day 2 (Figure 3Ac). The decrease in Pref-1 at the
protein level appears to precede that of Sox9 (Figure 3C, bottom
panel). We have previously reported that, of the two adipogenic
agents, DEX, but not MIX, suppresses Pref-1 expression. Simi-
larly, we found that DEX, but not MIX, effectively decreased
Sox9 mRNA levels by 70% after 12 hr of treatment (Figure 3Ad).
We conclude that suppression of Pref-1 and Sox9 is an early
event that precedes C/EBPa and PPARg induction but better
coincides and, in fact, precedes C/EBPb/C/EBPd induction.
We next tested whether Sox9 can inhibit 3T3-L1 adipocyte
differentiation, as was the case for MEF differentiation into
adipocytes. Both Pref-1 hFc treatment and constitutive overex-
pression of Pref-1 by 4-fold by Pref-1 lentivirus infection attenu-
ated adipocyte differentiation as judged by cell morphology,
oil red O staining, and expression of adipocyte markers FAS,
adiponectin, leptin ADSF/resistin, and aP2, as well as the adipo-
genic transcription factors C/EBPa and PPARg (Figure 3B).
Conversely, knockdown of Sox9 by 80% at the protein level by
Sox9 siRNA transfection resulted in enhanced adipocyte differ-
entiation compared to the control cells as judged by adipocyte
morphology, oil red O staining, and expression of adipocyte
markers (Figure 3C). Furthermore, in Sox9 siRNA-transfected
cells, Pref-1-hFc treatment could not bring about inhibition of
differentiation as observed by the same degree of adipocyte
differentiation as in Sox9 siRNA-transfected cells treated with
control hFc. These data clearly show that Sox9 inhibits adipo-
cyte differentiation and provide evidence that Pref-1 inhibition
of adipocyte differentiation is through Sox9.
We previously demonstrated Pref-1 inhibition of adipogenesis
in vivo by generatingmice lackingPref-1 aswell asmice express-
ing soluble Pref-1 in adipose tissue. Sox9 ablation inmice causes
embryonic lethality and thus could not be used to study adipo-
genesis that occurs mainly late after birth. In testing the Sox9
effect in vivo, we generated 3T3-F442A-GFP cells that either
stably overexpress Sox9 by 6-fold or have knockdown of Sox9
by 65%. These cells were implanted subcutaneously into immu-
nodeficient SCID mice. At 2 weeks after implantation, we deter-
mined lipid accumulation and adipocyte marker expression. As
Cell Metabolism
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(A) Pref-1 null MEFs were subjected to adipocyte differentiation in the presence of Pref-1-hFc or control hFc for 8 days. Oil red O staining (left panel), RT-PCR
(middle panel), and RT-qPCR (right panel). Results are mean ± SEM. **p < 0.01 compared to the cells in D0.
(B) Expression level of Sox9 was verified by western blotting (left panel) and by immunofluorescence 48 hr after infection (right panel).
(C) Pref-1 null MEFs overexpressing Sox9 by lentivirus infection were subjected to adipocyte differentiation in the presence of Pref-1-hFc or control hFc. Results
are mean ± SEM. **p < 0.01 compared to differentiated cells infected with control lentivirus or in the presence of hFc.shown in Figure 3D, control cells formed a substantial number of
adipocytes. On the other hand, the adipocytes that arose from
the implanted cells overexpressing Sox9 formed fewer adipo-
cytes. They showed lower oil red O staining, higher expression
of Pref-1, and lower expression of adipocyte markers such as
PPARg, adiponectin, and leptin. Conversely, implanted cells
expressing Sox9 shRNA formed a higher number of adipocytes
as detected by higher lipid staining and by lower expression of
Pref-1, as well as higher expression of PPARg, adiponectin,
and leptin. These results clearly demonstrate the inhibitory role
of Sox9 in adipogenesis in vivo.CSox9 Binds C/EBPb and C/EBPd Promoters to Suppress
Promoter Activity in Mediating Pref-1 Inhibition
of Adipogenesis
Because the decrease in Pref-1 and Sox9 expression upon treat-
ment with adipogenic agents precedes the early induction of
C/EBPb and C/EBPd (Figure 3A), we hypothesized that Sox9
may regulate C/EBPb and C/EBPd expression to affect adipo-
cyte differentiation. As shown in Figure 4A, overexpression of
Sox9 did not affect C/EBPa and PPARgmRNA levels but signif-
icantly suppressed C/EBPb and C/EBPd expression by 55% and
70%, respectively. Furthermore, cotransfection of Sox9 withell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc. 291
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activities by 80% or 85%, respectively (Figure 4B). However,
cotransfection of Sox9 with the shorter promoter-reporter
constructs, 0.5 kb C/EBPb-Luc or 1.0 kb C/EBPd-Luc, did not
affect the promoter activities. These data suggest that repres-
sion of C/EBPb and C/EBPd genes by Sox9 might be through
Sox9 binding between 1.0 and 0.5 kb of the C/EBPb
promoter and between 2.0 and 1.0 kb of the C/EBPd
promoter.
Examination of C/EBPb and C/EBPd promoter sequences re-
vealed the presence of, respectively, five and eight core
consensus binding sites for Sox9 (Figure 4C). ChIP analysis de-
tected evidence for Sox9 binding when specific primer pairs 3
and 4 for C/EBPb and specific primer pairs 3 and 4 for C/EBPd,
but not other primer sets, were used. Furthermore, EMSA with
in vitro translatedSox9protein andoligonucleotides correspond-
ing to the various Sox9 consensus sites showed that Sox9
can bind the 675–645 of the C/EBPb promoter and 1770–
1740 of C/EBPd promoter (Figure 4D). Excess cold oligonucle-
otides prevented the signals (Figure 4D, left panels), whereas the
oligonucleotides containing mutations of the core Sox9 binding
CAAT sequence did not affect the binding (Figure 4D, right
panels). Overall, these results demonstrate that Sox9 directly
binds its sites in the C/EBPb and C/EBPd promoter regions to
suppress promoter activity in mediating Pref-1 inhibition of
adipocyte differentiation.
Pref-1 Inhibits Osteoblast Differentiation
by Maintaining Sox9 Expression
Because we previously observed bone malformation in Pref-1
null and Pref-1 transgenic mice, we tested the effect of Pref-1
on osteoblast differentiation. First, we compared osteoblast
differentiation of MEFs from Pref-1 null, wild-type, and Pref-1
transgenic embryos. After 21 days of osteogenic induction, the
intensity of von Kossa staining was 3-fold higher in Pref-1 null
MEFs than in wild-type MEFs, whereas the staining was barely
detected in Pref-1 transgenic cells (Figure 5A, left panel). As pre-
dicted, northern blotting showed an absence of Pref-1 in Pref-1
null cells, whereas, in wild-type cells, endogenous Pref-1 was
detected at a low level, which was completely suppressed after
differentiation. In contrast, Pref-1 expression was high in Pref-1
transgenic cells, and the levels remained high after treatment
with osteogenic agents. After 21 days of osteoblast differentia-
tion, expression of ALPase and osteocalcin, respective early
and late osteogenic markers, increased drastically in Pref-1
null cells to levels exceeding those in wild-type cells, whereas
expression in Pref-1 transgenic cells was very low and did not
change. Similarly, ALPase activity in Pref-1 null cells was signif-
icantly higher than in wild-type cells after 7 days, and theCdifference was more marked as differentiation proceeded.
Thus, after 21 days of differentiation, ALPase activity in Pref-1
null cells increased by 15-fold, a level 3-fold higher than in
wild-type cells. The increase in ALPase activity was only 2-fold
in Pref-1 transgenic cells, 60% lower than the 5-fold increase
detected in wild-type cells. These data suggest that overexpres-
sion of Pref-1 inhibits, whereas lack of Pref-1 enhances, osteo-
blast differentiation in vitro. The inhibitory effect of Pref-1 on
osteoblast differentiation was further tested by using Pref-1-
hFc. As expected, the ALPase activity in Pref-1 null cells treated
with control hFc increased drastically and reached a 12-fold
increase at day 18 (Figure 5B). In contrast, ALPase activity in
cells treated with Pref-1-hFc increased in a delayed fashion
and was only 4-fold higher at day 18. ALPase and osteocalcin
mRNA levels at day 14 were markedly lower in cells treated
with Pref-1-hFc, showing Pref-1 inhibition of osteoblast differen-
tiation (Figure 5B).
We next examined the effect of Pref-1 on Sox9 expression
early in osteoblast differentiation of MEFs (Figure 5C). Treatment
with osteogenic agents drastically decreased Sox9 expression
after 24 hr in Pref-1 null MEFs (Figure 5Ca). Importantly, Pref-
1-hFcprevented this decrease. Expression of Runx2, a transcrip-
tion factor required for initiation of osteogenesis as well as
chondrocyte maturation, on the other hand, increasedmarkedly,
and this increase was also prevented by Pref-1-hFc treatment.
Similar to the effects observed in MEFs, Sox9 expression also
decreased drastically in C3H10T1/2 cells upon treatment with
osteogenic agents, which was prevented by Pref-1-hFc treat-
ment (Figure 5Cb). Unlike in MEFs and MC3T3 cells, however,
we could not detect Runx2 expression in C3H10T1/2 cells. After
24 hr of osteogenic treatment, Runx2 was clearly detected, and
Pref-1-hFc treatment prevented this Runx2 induction (data not
shown).
To further test the Pref-1 effect on Sox9 expression during
osteogenesis, we transfected Sox9 siRNA into C3H10T1/2 cells.
As expected, Sox9 siRNA transfection decreased Sox9 levels
markedly (Figure 5Cc). After 24 hr of treatment with osteogenic
agents, Pref-1-hFc prevented the drastic decrease in Sox9
expression observed in control siRNA-transfected cells. Expres-
sion of Runx2 was 3-fold higher in Sox9 siRNA-transfected cells
compared to control cells. More importantly, Pref-1 suppressed
Runx2 expression by 90% in control siRNA-transfected cells
treated with osteogenic agents, whereas Pref-1 was unable to
suppress Runx2 expression in Sox9 siRNA-transfected cells
(Figure 5Cc). These results show that Pref-1 inhibits osteoblast
differentiation by preventing Sox9 downregulation. We also de-
tected the Pref-1 effect by comparing osteoblast differentiation
of primary osteogenic cells from wild-type, Pref-1 null, and
Pref-1 transgenic E18.5 limbs and ribs (Figure S4). Overall, theseFigure 3. Pref-1 Inhibits 3T3-L1 Adipocyte Differentiation through Sox9
(A)RT-PCR (a) andRT-qPCR (bandc) for various adipocytemarkers during 3T3-L1adipocyte differentiation. RT-qPCRafter 12hr treatment (d). Results aremean±
SEM. **p < 0.01 compared to untreated cells.
(B) Sox9 protein level after 48 hr of infection (left panel). Morphology, oil red O staining (middle panel), and RT-qPCR and RT-PCR for adipocyte markers (right
panels). Results are mean ± SEM. **p < 0.01 compared to the cells infected with control lentivirus and treated with hFc.
(C) Sox9 knockdown enhances adipocyte differentiation. Western blotting after 48 hr siRNA transfection (left panel). Morphology, oil red O staining, and adipo-
cyte marker expression after adipocyte differentiation. **p < 0.01 compared to the cells transfected with control siRNA and treated with hFc.
(D) 3T3-F442A-GFP preadipocytes stably overexpressing or with knockdown of Sox9, or control cells (33 107 cells mixed with Matrigel matrix [BD] per site) were
injected subcutaneously into the back of SCID mice. The resulting tissues were dissected for oil red O and DAPI staining and RT-qPCR (n = 4/group). Results are
mean ± SEM. *p < 0.05. **p < 0.01 compared to the control.ell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc. 293
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through Sox9 regulation.
The effect of Pref-1 on osteoblast differentiation was also
tested in preosteoblasticMC3T3 cells (Figure 5D). Pref-1 expres-
sion was not detectable in MC3T3 cells (Figure 5D, top-left
panel). Osteocalcin and ALPase expression were very low in
confluent cells but increased markedly after 7 days of treatment
with osteogenic agents. These increases were blunted in cells
infected with Pref-1 lentivirus or upon Pref-1-hFc treatment.
Similarly, ALPase activity rapidly increased at day 3 and further
increased at days 6 and9 after osteogenic stimulation (Figure 5D,
top-right panel). The increase in ALPase activity was delayed and
significantly blunted at all time points in cells infected with Pref-1
lentivirus or upon Pref-1-hFc treatment. We also examined the
effect of Pref-1-hFc on expression of Sox9 early during osteo-
genesis in these cells (Figure 5D, bottom panels). During early
osteogenesis, expression of Sox9 was rapidly downregulated
by 50% within 1 hr after osteogenic stimulation in control hFc-
treated cells, andSox9 levels further decreased up to 2 days after
treatment, whereas expression of Runx2 was rapidly induced,
reaching a maximum of 3-fold at 4 hr that gradually decreased.
In contrast, the Sox9 expression level was maintained in cells
treated with Pref-1-hFc, whereas Runx2 expression did not
increase in these cells upon treatment with osteogenic agents.
Overall, these results show that Pref-1 prevents Sox9 downregu-
lation and thereby inhibits mesenchymal cell differentiation into
osteoblasts.
Pref-1 Directs Multipotent Mesenchymal Cells
to Chondrogenic Commitment but Inhibits Maturation
of Chondrocytes by Inducing Sox9 Expression
Because Pref-1 inhibits osteoblast differentiation and osteo-
blasts and chondrocytes are from common mesenchymal
progenitor cells, we hypothesized that Pref-1may regulate chon-
drocyte formation also (Gaur et al., 2005; Lengner et al., 2004).
Therefore, we compared MEFs from Pref-1 null, wild-type, and
Pref-1 overexpressing transgenic embryos in micromass culture
for chondrogenesis. Alcian blue staining showed the effect of
Pref-1 on chondrogenesis (Figure 6A, left panel): Pref-1 null cells
showed the weakest staining, and wild-type cells showed a
4-fold higher intensity of staining, which was even higher by
8-fold in transgenic cells. We used Col II and Col IX as immature
chondrocyte markers and Col X and ALPase as hypertrophic
chondrocyte markers. After 14 days of culture in the presence
of chondrogenic agents, wild-type cells showed 4.3-fold higher
Col II levels, and Pref-1 transgenic cells displayed 6.7-fold higher
Col II expression compared to Pref-1 null cells (Figure 6A, right
panel). On the contrary, Col X and ALPase expression were high-
est inPref-1 null cells. Upon treatmentwith chondrogenic agents,CALPase expression decreased by 4.7-fold in wild-type cells
but was not detected in Pref-1 transgenic cells. Col X expression
was also lower in Pref-1 transgenic cells. These results show that
Pref-1 promotes mesenchymal cell commitment to the chondro-
genic lineage but inhibits chondrocyte maturation in vitro.
Next, to test the effect of Pref-1 and Sox9 on chondrogenesis,
we infectedPref-1 null MEFswithSox9 lentivirus or treated Pref-1
null MEFs with Pref-1-hFc and subjected them to micromass
culture (Figure 6B). We found that Pref-1-hFc treatment or lenti-
virus-mediated Sox9 overexpression in MEFs caused increased
immature chondrocytes as judged by Alcian blue staining and
Col II and Col IX expression. Furthermore, overexpression of
Sox9 along with Pref-1-hFc treatment did not produce additive
effects, suggesting that Pref-1 and Sox9 may affect chondro-
genesis by the same mechanism. Similar results were obtained
from C3H10T1/2 cells subjected to chondrogenesis (data not
shown). To further examine the role of Sox9 in mediating the
Pref-1 effect on chondrogenesis, we treated the Pref-1 null MEFs
transfected with Sox9 siRNAwith soluble Pref-1-hFc (Figure 6C).
As judged by Alcian blue staining and chondrogenic marker
expression, we found that Pref-1-hFc treatment did not have an
effect on chondrogenesis in cells transfected with Sox9 siRNA,
compared to control cells treated with Pref-1 that had increased
immature chondrocytes. Overall, these data from MEFs and
C3H10T1/2 cells are consistent with the notion of Sox9 medi-
ating the Pref-1 effect and clearly demonstrate that, like Sox9,
Pref-1 can promote chondrogenic induction of uncommitted
mesenchymal cells in micromass culture.
We also tested the involvement of Sox9 and Pref-1 in chondro-
cyte maturation by employing committed chondrogenic cells
from skinned tails from newborn mice in micromass culture (Fig-
ures 7A and 7B). After 14 days of culture, compared to wild-type
cells, Pref-1 null cells displayed a lower intensity of Alcian blue
staining with a lower expression of Col II and Col IX but higher
expression of Col X and ALPase. In contrast, Pref-1 transgenic
cells displayed stronger Alcian blue staining with higher Col II
and Col IX but lower Col X and ALPase expression (Figure 7A).
In addition, Sox9 expression was lower, whereas Runx2 was
higher in Pref-1 null cells than in wild-type cells, and Pref-1 trans-
genic cells showed higher Sox9 expression but lower Runx2
expression. We also found that expression of the prehypertro-
phic marker, Ihh, was higher in Pref-1 null cells but was lower
in Pref-1 transgenic cells than in wild-type cells. These observa-
tions demonstrate that Pref-1 increases immature chondrocytes
but inhibits maturation of chondrocytes. Furthermore, Pref-1
lentivirus infection or Pref-1-hFc treatment increased immature
chondrocytes as judged by Alcian blue staining and chondro-
genic marker expression with increased Col II and Col IX expres-
sion but decreased Col X expression. These observationsFigure 4. Sox9 Directly Binds C/EBPb and C/EBPd Promoters and Suppresses Their Transcription
(A) RT-qPCR for various transcription factors 72 hr after Sox9 transfection into 3T3-L1 cells. *p < 0.05 and **p < 0.01 compared to cells transfected with
empty vector.
(B) C/EBPb and C/EBPd promoter activity after cotransfection with Sox9 into 293FT cells. pRL-SV40 was used as internal control. Results are mean ± SEM.
**p < 0.01.
(C) Numbering denotes primer sets in the C/EBPb and C/EBPd promoter regions used for ChIP (left panel). ChIP for C/EBPb and C/EBPd using 3T3-L1 cells (right
panel). Bar, sites with core consensus Sox9 binding sequence. Star, actual Sox9 binding sites.
(D) EMSA for Sox9 binding sites. In vitro translated Sox9 protein and 32P-labeled oligonucleotides were used for EMSA. Probe only (lane 1); 1 ml (lane 2) and 2 ml
(lane 3) of Sox9 translation reaction with probe; 1 ml of Sox9 with 100 3 wild-type competitor (lane 4); 1 ml of translation reaction of empty pcDNA3.1 vector with
probe (lane 5); 1 ml of Sox9 with 100 3 mutant competitor (lane 6).ell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc. 295
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induction/early chondrocyte differentiation but inhibits chondro-
cyte maturation. Thus, Pref-1 maintains the chondrocytes in an
immature state and prevents their differentiation into mature
chondrocytes in vitro. When we tested the effect of Pref-1 on
Sox9 and Runx2 expression in Pref-1 null primary chondrogenic
cells (Figure 7B, left panel), Sox9 expression increased by
4.6-fold after 1 hr of Pref-1-hFc treatment. On the other hand,
we did not detect any significant changes in Runx2 expression at
this time point, further suggesting that Pref-1 function is through
Sox9 induction.
As mentioned, in adults, Pref-1 expression is mainly restricted
to preadipocytes as well as some neuroendocrine cell types, but
Pref-1 is widely expressed during embryonic development with
prominent expression in developing vertebra as shown by
in situ hybridization at day E13.5 (Figure 7C). In vertebra, Pref-1
expression was restricted to the periphery of vertebral bodies
but was undetectable in hypertrophic zones (Figure 7C, bottom
panel), suggesting that Pref-1 functions in immature chondro-
cytes, but not in hypertrophic chondrocytes. To demonstrate
the effects of Pref-1 on chondrogenesis in vivo, we examined
embryonic developmental stages by comparing Pref-1 null,
wild-type, andPref-1 transgenic embryos. Asshown inFigure 7D,
we did not observe drastic malformation at E14.5 when mesen-
chymal condensations start to commit to the chondrocyte linage
and, in part, to become prehypertrophic chondrocytes. But, the
prehypertrophic marker, Ihh, was strongly expressed in Pref-1
null vertebral bodies compared to wild-type, whereas it was
barely detectable in Pref-1 overexpressing vertebral bodies. In
contrast, expression of the immature chondrocyte marker, Col II,
was lower in Pref-1 null embryos but was strongly expressed in
Pref-1 overexpressing embryos. At E16.5 stage,when the central
vertebral bodies normally become hypertrophic chondrocytes,
both Pref-1 null and Pref-1 overexpressing embryos showed
more visible skeletal malformation (Figure 7E). Compared to
wild-type, Pref-1 null embryos were smaller, with higher expres-
sion of the prehypertrophic and hypertrophic chondrocyte
markers, Ihh and Col X, respectively. Pref-1 transgenic embryos
were also smaller, with shorter kinky tails, and showed higher
expression of the immature chondrocyte marker Col II andmark-
edly lower expression of the prehypertrophic and hypertrophic
markers, Ihh and Col X.
Phenotypesweremoresevere in thenewbornstage (Figure7F).
Histological staining of the vertebral region showed that,
compared towild-typemice, Pref-1 nullmice had a 40% increase
in the hypertrophic zone, whereas the hypertrophic zone was
absent in Pref-1 transgenic mice (Figure 7F). Similarly, we
detected a 40% increase in the hypertrophic zone in Pref-1 null
long bones (E18.5 femurs) compared to wild-type mice, whereasCwe found a 25%–30% decrease in the hypertrophic zone in
Pref-1 transgenic mice (data not shown). Conversely, the zone
of immature chondrocytes was 30% lower in Pref-1 null mice,
whereas Pref-1 transgenic mice had only immature chondro-
cytes without an obvious hypertrophic zone. As expected, by
northern blot analysis, Pref-1 was not detected in Pref-1 null
mice but was markedly higher in Pref-1 transgenic mice. Simi-
larly, Sox9 expression was significantly lower in Pref-1 null mice
compared towild-typemice butwas 6-fold higher in Pref-1 trans-
genic mice. Examination of chondrocyte/osteoblast marker
expression also indicated that the levels of immature chondro-
cyte markers, including Col II and aggrecan, were lower in
Pref-1 null mice but higher in Pref-1 transgenic mice compared
to wild-typemice. In contrast, expression of mature chondrocyte
marker Col X and hypertrophic/early osteogenic marker ALPase
was higher in Pref-1 null mice but barely detectable in Pref-1
transgenic mice. Overall, these data show that Pref-1 brings
about chondrogenic induction but inhibits chondrocyte
maturation.
Effect of Pref-1 on Bone Marrow Stromal Cell Fate
Because bone marrow mesenchymal stem cells (MSC) can
commit and differentiate into adipocytes as well as chondro-
cytes and Pref-1 is detected in bone marrow, we next examined
the presence of adipocytes in bone marrow of 1-week-old verte-
bral bodies from Pref-1 null, wild-type, and Pref-1 transgenic
mice. H&E staining showed that rounded adipose features
were higher in Pref-1 null than in wild-type vertebra, and they
were barely detectable in Pref-1 overexpressing vertebra (Fig-
ure 7G, upper panel). Expression of adipocyte markers in bone
marrow from 12-week-old femur bone was inversely correlated
with Pref-1 expression. C/EBPa, PPARg, and adiponectin levels
were markedly higher in Pref-1 null bone marrow but were very
low in Pref-1 transgenic ones. In contrast, Sox9 expression
levels were very low in Pref-1 null bone marrow but were mark-
edly higher in Pref-1 transgenic bone marrow (Figure 7G, lower
panel). Overall, these observations indicate a potential in vivo
effect of Pref-1 on MSC differentiation into adipocytes.
We next used the humanMSC in culture to test whether Pref-1
affects the fate of these cells during adipogenic and chondro-
genic commitment/differentiation (Figure 7H). RT-qPCR showed
that, 2 days after initiation of adipocyte differentiation, Sox9 as
well as endogenous Pref-1 expression levels were significantly
higher in Pref-1-hFc-treated cells compared to control hFc-
treated cells (Figure 7H, upper panel). On the other hand, expres-
sion levels of adipocyte markers, C/EBPb, C/EBPd, and PPARg
were lower in Pref-1-hFc-treated cells. Upon treatment with
chondrogenic agents of MSC for 2 days, Sox9 and Col II expres-
sion levels were significantly higher in Pref-1-hFc-treated cellsFigure 5. Pref-1 Inhibits Osteoblast Differentiation by Preventing the Decrease in Sox9 Expression
(A) Von Kossa staining of MEFs after 21 days of osteoblast differentiation (left panel). Northern blot analysis (middle panel) and ALPase activity (right panel).
Results are means ± SEM. *p < 0.05 and **p < 0.01 compared to wild-type cells at indicated time points.
(B) ALPase activities (left panel) and northern blotting after 18 days of osteoblast differentiation (right panel).
(C) RT-qPCR for Pref-1 null MEFs and C3H10T1/2 cells cultured for in osteogenic media (a and b). siRNA-transfected C3H10T1/2 cells cultured in osteogenic
media (c). For Sox9 expression, the value of untreated cells was defined as 1. For Runx2, due to its undetectable level in untreated cells, the value of control
siRNA-transfected cells after 24 hr treatment was defined as 1.
(D) RT-PCR after 48 hr lentivirus infection in MC3T3 cells. Northern blot analysis from confluent MC3T3 cells (D0), 7 days osteogenic treatment (D7), and ALPase
activity. Results are mean ± SEM. **p < 0.01 compared to cells infected with control lentivirus and cultured with hFc at indicated time points. RT-qPCR during
osteogenic differentiation (bottom panel).ell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc. 297
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Pref-1 in Mesenchymal Cell FateFigure 6. Pref-1 Directs MEF Commitment to Chondrogenic Lineage through Sox9 Regulation
(A) Micromass culture of MEFs. Alcian blue staining (left panel) and RT-PCR for chondrogenic markers (right panel) after 14 days of culture.
(B) Pref-1 null MEFs infectedwith Sox9 lentivirus after 10 daysmicromass culture. **p < 0.01 compared to differentiated cells infectedwith control empty lentivirus
and in the presence of control hFc.
(C) Knockdown of Sox9 blocks chondrogenic induction by Pref-1. Alcian blue staining for Pref-1 null MEFs transfected with siRNA after micromass culture.
Western blotting after 48 hr transfection (left top panel). Results are mean ± SEM. *p < 0.05 and **p < 0.01 compared to cells transfected with control siRNA
and treated with hFc.compared to control hFc cells, demonstrating promotion to the
chondrogenic lineage by Pref-1 (Figure 7H, lower panel). Overall,
these results from MSC in culture further confirm that Pref-1
promotes commitment to the chondrocyte lineage but inhibits
adipogenesis.
298 Cell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc.DISCUSSION
We previously reported Pref-1 inhibition of adipocyte differentia-
tion by both in vitro and in vivo approaches. In fact, we originally
identified Pref-1 as a protein found in preadipocytes, but not in
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Pref-1 in Mesenchymal Cell Fateadipocytes. During adipocyte differentiation, Pref-1 is extin-
guished. Constitutive expression of Pref-1 inhibits 3T3-L1 pre-
adipocyte differentiation into adipocytes, and Pref-1 knockdown
causes enhanced differentiation. The significance of Pref-1 func-
tion in adipogenesis has been documented in vivo in Pref-1 null
and Pref-1 overexpressing transgenic mice. Although expres-
sion of the two key adipogenic transcription factors C/EBPa
and PPARg clearly is suppressed by Pref-1 treatment, the prox-
imal downstream molecule that mediates Pref-1 inhibition has
not been defined. It has been reported previously that HES-1
expression is induced by Pref-1 treatment in thymocytes (Kaneta
et al., 2000). However, we could not detect any changes in
HES-1 expression by Pref-1 (unpublished data). In the present
study, we show that Sox9 is a target of Pref-1, and Pref-1
increases Sox9 expression rapidly in various cell types, including
multipotent mesenchymal cells. Although a receptor for Pref-1
has not been identified, we have previously shown that Pref-1
activates the MEK/ERK pathway. The fact that Sox9 is known
to be induced by ERK activation (Murakami et al., 2000) and that
inhibition of Pref-1-mediated ERK activation prevents Sox9
induction further supports the notion of Sox9 as a downstream
target of Pref-1. In this regard, although Sox9 may not be the
only target for Pref-1, we found that Pref-1 expression parallels
Sox9 expression during adipocyte differentiation of MEFs and
3T3-L1 cells, as well as during in vivo adipogenesis.
Although the role of Sox9 in chondro- and osteogenesis is well
understood, its role in adipocyte commitment/differentiation has
not been studied. Here, we show that overexpressing Sox9
constitutively or maintaining Sox9 levels by treating the cells
with Pref-1-hFc cause inhibition of adipocyte differentiation. We
conclude that Sox9 suppression is required before induction of
the adipogenic transcription factors PPARg and C/EBPa for
adipocyte differentiation. Furthermore, downregulation of Sox9
coincides with the induction of C/EBPb/C/EBPd that occurs
earlier thanC/EBPa and PPARg induction. Suppression of Pref-1
decreases Sox9 expression that, in turn, allows C/EBPb and
C/EBPd induction early at the start of adipocyte differentiation. A
synthetic glucocorticoid DEX, routinely used for adipocyte differ-
entiation, suppresses Pref-1 expression. We also found that DEX
suppresses Sox9 expression also. We thus predicted that Sox9
might function through regulating C/EBPb and/or C/EBPd during
adipocyte differentiation. In this regard, glucocorticoids have
been reported to induce C/EBPd expression. In the present
study, we detected suppression of C/EBPd and C/EBPb upon
Sox9 overexpression. Furthermore, cotransfection of Sox9 re-
sulted in decreased C/EBPb and C/EBPd promoter activity, and
EMSA and ChIP analysis revealed the binding sites of Sox9 at
675–645 of C/EBPb and 1770–1740 of C/EBPd promoter
sequences. Here, we also demonstrate in vivo the role of Sox9
in adipogenesis by subcutaneous implanting (Figure 3D). The
present study demonstrates that Sox9 is downregulated during
adipocyte differentiation and Sox9 inhibits adipocyte differentia-
tion. Our study also shows that the function of Sox9 is to maintain
cells in the preadipocyte stage by directly binding to the C/EBPb
and C/EBPd promoter regions to suppress transcription.
Pref-1 is expressed inmultipotentmesenchymal stemcells that
can differentiate into several cell types, including chondrocytes,
osteoblasts, and adipocytes. Although the role of Pref-1 in adipo-
genesis has been extensively studied (Lee et al., 2003; Mei et al.,C2002; Moon et al., 2002; Smas et al., 1998), Pref-1 effects on
chondrocyte commitment andmaturation have not been studied
before. Here, we employedMEFs that have the ability to undergo
commitment/differentiation into various mesenchymal lineages,
including chondrocytes, osteoblasts, and adipocytes. Sox9 and
Pref-1 have similar, but not additive, effects onMEF commitment
and early differentiation into immature chondrocytes. We also
employed bone marrow stromal cells to demonstrate that Pref-1
inhibits adipogenesis while promoting chondrogenic commit-
ment. Examination of the bone marrow clearly shows that Pref-1
expression is inversely correlated with adipose morphology
in vivo. Moreover, chondrogenic induction by Pref-1 in micro-
mass culture is abolished in the absence of Sox9, evidence that
Sox9 mediates the Pref-1 effect of promoting chondrogenic
induction. It is well recognized that Sox9 plays an essential role
in recruiting mesenchymal cells to undergo chondrogenic
commitment and early chondrogenesis but inhibits maturation
to hypertrophic chondrocytes (Akiyama et al., 2004). Sox9 func-
tion in chondrogenesis has been documented by loss- and
gain-of-function studies in vitro and in vivo (de Crombrugghe
et al., 2001). InactivationofSox9beforemesenchymal condensa-
tion in mice results in the complete prevention of condensation
and cartilage formation. Thus, Sox9 deficiency and Sox9 overex-
pression in mice result in smaller skeletons as seen in Pref-1 null
and Pref-1 transgenic mice. Pref-1 null mice appear to have,
albeit less severely, phenotypes of skeletal development resem-
bling phenotypes foundwhen Sox9 is knocked down ormutated,
whereas the phenotypes of Pref-1 transgenic mice have similari-
ties to the Sox9 transgenic mouse model. In this regard, defi-
ciencies in some of the known growth factors/hormones that
affect skeletogenesis, at least in part, through Sox9 regulation
also have similar phenotypes (Karaplis et al., 1994; Liu et al.,
2002). Regardless, these apparent phenotypic similarities of
in vivo gain and loss of function further support the notion that
Pref-1 effects are through regulation of Sox9 expression.
With our present study demonstrating the role of Pref-1 on
chondrogenesis, the Pref-1 effect on bone formation could be
an indirect one. However, the Pref-1 effect on MEFs, as well as
preosteoblastic MC3T3 cells that can undergo osteoblast differ-
entiation in vitro, indicates a direct inhibitory effect of Pref-1 on
osteoblast differentiation. This idea is also supported by a
previous report of Pref-1 leading to inhibition of osteoblast differ-
entiation of human bone marrow stromal cells (Abdallah et al.,
2004). More importantly, we demonstrate here that Pref-1
prevents Sox9 downregulation and thereby inhibits osteoblast
differentiation and the expression of the osteogenic transcription
factor Runx2. Progenitor cells in early mesenchymal condensa-
tions have dual differentiation potentials, as they coexpress
Sox9 and Runx2. Runx2 has been shown to accelerate chondro-
cyte maturation to become hypertrophic chondrocytes and to
promote osteogenesis (Takeda et al., 2001). Runx2 appears to
exert its function only when Sox9 is downregulated in hypertro-
phic chondrocytes or in osteoblasts. We conclude that Pref-1
inhibits osteoblast differentiation by preventing downregulation
of Sox9.
In conclusion, we show here that Sox9 downregulation is
required for adipocyte differentiation. Sox9 suppresses C/EBPb/
C/EBPd expression by directly binding to its sites in the promoter
regions of these genes. Importantly, we demonstrate that Pref-1ell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc. 299
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Pref-1 in Mesenchymal Cell FateFigure 7. Pref-1 Promotes Chondrogenic Induction but Inhibits Chondrocyte Maturation through Upregulation of Sox9
(A) Micromass culture of cells from newborn tails. Alcian blue staining and RT-PCR and RT-qPCR for chondrogenic markers. **p < 0.01 compared to wild-type.
(B) RT-qPCR after 1 hr treatment with 50 nM Pref-1-hFc (left panel). **p < 0.01 compared to untreated cells. RT-PCR in cells 48 hr after infection.
(C) In situ hybridization of E13.5 embryos with 33P-labeled Pref-1 antisense probe (left panel) and bright field view with hematoxylin staining (left panel). Thoracic-
abdominal vertebra region is enlarged (bottom). Disc, spinal disc. Hyp, hypertrophic zone.
(D–F) Embryos and mice and their skeleton staining (Alcian blue for cartilage and alizarin red for bone) in various developmental stages.
(F) Thoracic-abdominal vertebra was used for in situ hybridization with digoxigenin labeled antisense probe. H&E staining of fourth through fifth coccyges from
newborn mice (middle panel). Color bars represent the length of different histological area. Red bar, zones of hypertrophic chondrocytes. Blue bar, the area of300 Cell Metabolism 9, 287–302, March 4, 2009 ª2009 Elsevier Inc.
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Pref-1 in Mesenchymal Cell Fateinhibition of adipogenesis is through maintaining Sox9 expres-
sion. We also show that, by inducing Sox9, Pref-1 promotes
chondrogenic induction of mesenchymal cells but prevents
chondrocyte maturation as well as osteoblast differentiation,
with supporting in vivo evidence in Pref-1 null and Pref-1 trans-
genic mice. Overall, Sox9 is a Pref-1 target, and Pref-1 directs
multipotent mesenchymal cells to the chondrogenic lineage
but inhibits differentiation into adipocytes, as well as osteoblasts
and chondrocytes.
EXPERIMENTAL PROCEDURES
Lentiviral and Plasmid Constructs and Animals
The lentiviral constructwasmadeby subcloningSox9 intopLenti6/V5-D-TOPO
vector. Sox9 was also subcloned into pcDNA3.1. The 1.0-C/EBPb-luc, 0.5-C/
EBPb-luc, 2.0-C/EBPd-luc, and 1.0-C/EBPd-luc were generated by inserting
1.0 and 0.5 kb C/EBPb and 2.0 and 1.0 kb C/EBPd 50 flanking regions into
the pGL2 basic vector (Promega). Sox9 shRNA plasmid was purchased from
SABiosciences. The generation of Pref-1 null and Pref-1 transgenic mice
were described previously (Lee et al., 2003; Moon et al., 2002). Scid mice
were purchased from the Jackson laboratory.
Cells and siRNA Transfection
MC3T3 cells were cultured in a-MEM (Invitrogen) containing 10% FBS. MEFs
were prepared from E13.5 embryos as described previously (Wang and Sul,
2006). Human-derived marrow stromal cells (MSC) and MSC media were
purchased from Allcells. Sox9 target-specific siRNA (sc-36534) (Santa Cruz)
and the control siRNA (sc-36869) were transfected into cells using transfection
reagent (Santa Cruz).
Chromatin Immunoprecipitation and Electrophoretic
Mobility Shift Assay
For chromatin immunoprecipitation (ChIP) analysis, 13 107 3T3-L1 cells were
crosslinked with 1% formaldehyde before nuclei preparation. After sonication,
DNA sizes were 0.3–0.9 kb. Ten percent of the total volume was used as input,
and the rest was divided into two fractions: one for control IgG and the second
for 5 mg of Sox9 antibody immunoprecipitation. Purified DNA was used in PCR
reactions.
Sox9 protein was in vitro translated using Promega TNT Translation
Systems and used in electrophoretic mobility shift assay (EMSA). Sense and
antisense oligonucleotides (30 bp) containing potential Sox9 core-binding
sequence CAAT were labeled by g 32P-dCTP. Mutant competitors were the
oligonucleotides mutated CAAT to CCAT. Samples were separated by 5%
native polyacrylamide gel electrophoresis before exposure to film.
Statistical Analysis
Data are expressed as the mean ± SEM. The statistical differences in mean
values were assessed by Student’s t test. All experiments are repeated at least
twice, and representative data are shown. All scanned images were quantified
by NIH image software.
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The Supplemental Data include Supplemental Experimental Procedures and
five figures and can be found with this article online at http://www.cell.com/
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